The PICO (Population, Intervention, Comparison, Outcome) framework guided the inclusion of studies involving NSCLC patients or human cell lines, reporting on C3a/C5a levels and their association with clinical outcomes or pro-tumoral effects. This evidence concerns the gene C3 and non-small cell lung carcinoma.